Related Experiment Video

Updated: Aug 20, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

484

USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective

Georgiy Korenev1, Sergey Yakukhnov1, Anastasia Druk1

  • 1Scientific Center for Translational Medicine, Sirius University, 354349 Sirius, Russia.

Cancers
|November 26, 2022
PubMed

Insights

Ubiquitin-specific protease 7 (USP7) is a cancer target that suppresses anti-tumor immunity. Inhibiting USP7 shows promise for cancer immunotherapy by restoring immune balance and improving patient survival.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Ubiquitin-specific protease 7 (USP7) overexpression is linked to poor cancer survival.
  • USP7 regulates proteins involved in suppressing anti-tumor immune responses.
  • USP7 inhibition can restore the p53 tumor suppressor's stability by modulating the p53/MDM2 axis.

Purpose of the Study:

  • To review recent advancements in understanding USP7's role in cancer.
  • To explore USP7's interactions with molecular pathways.
  • To discuss the therapeutic potential of targeting USP7 in cancer treatment.

Main Methods:

  • Literature review of USP7's function in cancer.
  • Analysis of USP7's impact on immune cells (T cells, macrophages).
  • Evaluation of USP7 inhibitors' efficacy in preclinical models.

Main Results:

  • USP7 inhibition can enhance anti-tumor immunity by affecting regulatory T cells, tumor-associated macrophages, and PD-L1 expression.
  • Small-molecule USP7 inhibitors have demonstrated in vivo efficacy.
  • Combining USP7 inhibition with cancer immunotherapy presents a promising therapeutic strategy.

Conclusions:

  • USP7 plays a critical role in regulating anti-tumor immune responses and cancer progression.
  • Targeting USP7 offers a potential therapeutic avenue for various cancers.
  • Further clinical studies are needed to validate the efficacy of USP7 inhibitors in combination with immunotherapy.
Keywords:
cancerimmunotherapysmall-molecule inhibitorsubiquitin-specific protease 7

More Related Videos

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
630
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
482
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K